Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas V Faller

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Blood|October 18, 2003
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemiaRebecca J Greenwald, Joseph R Tumang, Anupama Sinha, et al.
Investigational New Drugs|October 22, 2020
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [<sup>14</sup>C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Farhad Sedarati, Douglas V Faller, et al.
Pharmacoeconomics - Open|October 17, 2018
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United StatesJill A Bell, Aaron Galaznik, Marlo Blazer, et al.
Targeted Oncology|April 12, 2022
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Journal of Patient-Reported Outcomes|June 21, 2019
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaJill A Bell, Aaron Galaznik, Farrah Pompilus, et al.
Leukemia Research|June 27, 2018
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United StatesJill A Bell, Aaron Galaznik, Eileen Farrelly, et al.
Targeted Oncology|November 29, 2021
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Leukemia Research|February 5, 2019
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agentJill A Bell, Aaron Galaznik, Eileen Farrelly, et al.
Bioresearch Open Access|November 4, 2017
Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us SomethingKrishna Kodukula, Douglas V Faller, David N Harpp, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Blood|October 18, 2003
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemiaRebecca J Greenwald, Joseph R Tumang, Anupama Sinha, et al.
Investigational New Drugs|October 22, 2020
Phase I study assessing the mass balance, pharmacokinetics, and excretion of [<sup>14</sup>C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Farhad Sedarati, Douglas V Faller, et al.
Pharmacoeconomics - Open|October 17, 2018
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United StatesJill A Bell, Aaron Galaznik, Marlo Blazer, et al.
Targeted Oncology|April 12, 2022
Correction to: A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Investigational New Drugs|August 6, 2022
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumorsXiaofei Zhou, Ulka Vaishampayan, Devalingam Mahalingam, et al.
Journal of Patient-Reported Outcomes|June 21, 2019
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemiaJill A Bell, Aaron Galaznik, Farrah Pompilus, et al.
Leukemia Research|June 27, 2018
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United StatesJill A Bell, Aaron Galaznik, Eileen Farrelly, et al.
Targeted Oncology|November 29, 2021
A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological MalignanciesToshio Shimizu, Yasutoshi Kuboki, Chia-Chi Lin, et al.
Leukemia Research|February 5, 2019
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agentJill A Bell, Aaron Galaznik, Eileen Farrelly, et al.
Bioresearch Open Access|November 4, 2017
Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us SomethingKrishna Kodukula, Douglas V Faller, David N Harpp, et al.
Pageof 13